Phase II evaluation of gefitinib in patients with newly diagnosed grade 4 astrocytoma: Mayo/north central cancer treatment group study n0074 Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Brain Neoplasms
  • Glioblastoma
  • Quinazolines
  • Receptor, Epidermal Growth Factor

abstract

  • In our evaluation of nearly 100 patients with newly diagnosed GBM, treatment with adjuvant gefitinib post-radiation was not associated with significant improvement in OS or PFS. However, patients who experienced gefitinib-associated adverse effects (rash/diarrhea) did demonstrate improved OS.

publication date

  • June 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ijrobp.2010.01.070

PubMed ID

  • 20510539

Additional Document Info

start page

  • 347

end page

  • 53

volume

  • 80

number

  • 2